PharmiWeb.com - Global Pharma News & Resources

Press Releases - 2022-01-26

Date Title Company
26-Jan-2022 HMNC Brain Health Expands International Patent Portfolio with Two Stress-axis Related Substances for Major Depressive Disorder HMNC Brain Health
26-Jan-2022 Genmab Announces Net Sales of DARZALEX® (daratumumab) for 2021 Genmab
26-Jan-2022 Immutep quarterly activities report and Appendix 4C Immutep
26-Jan-2022 First patient dosed in randomised Phase 2 clinical trial of MTL-CEBPA in patients with advanced liver cancer MiNA Therapeutics Limited
26-Jan-2022 Sareum to Participate in the Edison Group’s Global Healthcare “Open House” Virtual Conference (25-27 January 2022) Sareum Holdings plc
26-Jan-2022 ElmediX raises nearly 12 million euros to develop innovative heat technology to fight cancer ElmediX
26-Jan-2022 Cytovation raises $20 million in Series A financing round to advance clinical development of CyPep-1, a first-in-class targeted tumor membrane immunotherapy Cytovation AS
26-Jan-2022 TrakCel and Körber partner to provide orchestration within manufacturing of cell and gene therapies TrakCel
26-Jan-2022 CONFERENCE SERIES WIDENS INVESTOR ACCESS TO CUTTING-EDGE HEALTHCARE STOCKS Edison Group
26-Jan-2022 Scottish bio-tech uFraction8 secures £2.5m commercialisation investment uFraction8
26-Jan-2022 NICE EXPANDS GUIDANCE FOR LOKELMA®▼(sodium zirconium cyclosilicate) IN ADULT PATIENTS WITH PERSISTENT HYPERKALAEMIA AstraZeneca
26-Jan-2022 LoQus23 Therapeutics appoints Dr. Melanie Ivarsson, OBE, as Non-Executive Director LoQus23 Therapeutics
26-Jan-2022 OWEN MUMFORD ANNOUNCES ON MARKET RELEASE OF UNISAFE® 1mL SAFETY DEVICE FOR PRE-FILLED SYRINGES FEATURING INDUSTRY-FIRST SPRINGLESS MECHANISM Owen Mumford
26-Jan-2022 Beckley Psytech announces first cohort of psychotherapists have begun training for treatment resistant depression Phase 2 trials Beckley Psytech
26-Jan-2022 Verona Pharma Completes Enrollment in Phase 3 ENHANCE-2 Trial Evaluating Ensifentrine for Maintenance Treatment of COPD Verona Pharma
26-Jan-2022 Two Weeks to go until the RNA Therapeutics Conference Takes Place SMi Group
26-Jan-2022 Roche’s Evrysdi (risdiplam) granted FDA priority review for treatment of pre-symptomatic babies under 2 months of age with spinal muscular atrophy (SMA) Roche
26-Jan-2022 Defence Therapeutics Inc.: Defence's AccumTM-HPV vaccine formulation (AccuVAC-PT009) activates a 36-fold higher humoral response compared to Gardasil-9 Defence Therapeutics Inc.
26-Jan-2022 Queen’s University Belfast enters collaboration and licensing agreement with Ipsen to progress FLIP inhibitor project which has been supported by Domainex Sciad Newswire
26-Jan-2022 Xlife Sciences raises CHF 5.0 million through capital increase Xlife Sciences AG